Strong Revenue and EPS Growth
Agilent delivered revenue of $1.67 billion for Q2, representing a 6% reported growth and 5.3% core growth compared to Q2 2024. EPS grew by 7% to $1.31, marking the fourth consecutive quarter of accelerating growth.
Geographic and Market Segment Growth
All regions grew in the quarter, with China leading at 10% growth. Diagnostics and Clinical grew 8%, and Environmental and Forensics grew 6% on strong PFAS testing demand. The Agilent CrossLab Group reported revenue growth of 9%.
PFAS Testing Demand Surge
PFAS grew more than 70% year-over-year globally, with Europe and China more than doubling their business. PFAS testing is expected to expand, contributing significantly to growth.
Successful Launch of New Products
Agilent launched the Seahorse XF Flex analyzer and the InfinityLab Pro iQ series, enhancing capabilities in cellular metabolism and liquid chromatography mass detection.
Continued Investment in Digital Ecosystem
Agilent grew digital orders by 12% year-over-year to $295 million, reflecting successful investments in their digital ecosystem.